Cargando…
DPP4 as a Potential Candidate in Cardiovascular Disease
The rising prevalence of cardiovascular disease has become a global health concern. The occurrence of cardiovascular disease is the result of long-term interaction of many risk factors, one of which is diabetes. As a novel anti-diabetic drug, DPP4 inhibitor has been proven to be cardiovascular safe...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488155/ https://www.ncbi.nlm.nih.gov/pubmed/36147690 http://dx.doi.org/10.2147/JIR.S380285 |
_version_ | 1784792598457614336 |
---|---|
author | Chen, Si-Yu Kong, Xiang-Quan Zhang, Ke-Fan Luo, Shuai Wang, Feng Zhang, Jun-Jie |
author_facet | Chen, Si-Yu Kong, Xiang-Quan Zhang, Ke-Fan Luo, Shuai Wang, Feng Zhang, Jun-Jie |
author_sort | Chen, Si-Yu |
collection | PubMed |
description | The rising prevalence of cardiovascular disease has become a global health concern. The occurrence of cardiovascular disease is the result of long-term interaction of many risk factors, one of which is diabetes. As a novel anti-diabetic drug, DPP4 inhibitor has been proven to be cardiovascular safe in five recently completed cardiovascular outcome trials. Accumulating studies suggest that DPP4 inhibitor has potential benefits in a variety of cardiovascular diseases, including hypertension, calcified aortic valve disease, coronary atherosclerosis, and heart failure. On the one hand, in addition to improving blood glucose control, DPP4 inhibitor is involved in controlling cardiovascular risk factors. On the other hand, DPP4 inhibitor directly regulates the occurrence and progression of cardiovascular diseases through a variety of mechanisms. In this review, we summarize the recent advances of DPP4 in cardiovascular disease, aiming to discuss DPP4 inhibitor as a potential option for cardiovascular therapy. |
format | Online Article Text |
id | pubmed-9488155 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-94881552022-09-21 DPP4 as a Potential Candidate in Cardiovascular Disease Chen, Si-Yu Kong, Xiang-Quan Zhang, Ke-Fan Luo, Shuai Wang, Feng Zhang, Jun-Jie J Inflamm Res Review The rising prevalence of cardiovascular disease has become a global health concern. The occurrence of cardiovascular disease is the result of long-term interaction of many risk factors, one of which is diabetes. As a novel anti-diabetic drug, DPP4 inhibitor has been proven to be cardiovascular safe in five recently completed cardiovascular outcome trials. Accumulating studies suggest that DPP4 inhibitor has potential benefits in a variety of cardiovascular diseases, including hypertension, calcified aortic valve disease, coronary atherosclerosis, and heart failure. On the one hand, in addition to improving blood glucose control, DPP4 inhibitor is involved in controlling cardiovascular risk factors. On the other hand, DPP4 inhibitor directly regulates the occurrence and progression of cardiovascular diseases through a variety of mechanisms. In this review, we summarize the recent advances of DPP4 in cardiovascular disease, aiming to discuss DPP4 inhibitor as a potential option for cardiovascular therapy. Dove 2022-09-16 /pmc/articles/PMC9488155/ /pubmed/36147690 http://dx.doi.org/10.2147/JIR.S380285 Text en © 2022 Chen et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Chen, Si-Yu Kong, Xiang-Quan Zhang, Ke-Fan Luo, Shuai Wang, Feng Zhang, Jun-Jie DPP4 as a Potential Candidate in Cardiovascular Disease |
title | DPP4 as a Potential Candidate in Cardiovascular Disease |
title_full | DPP4 as a Potential Candidate in Cardiovascular Disease |
title_fullStr | DPP4 as a Potential Candidate in Cardiovascular Disease |
title_full_unstemmed | DPP4 as a Potential Candidate in Cardiovascular Disease |
title_short | DPP4 as a Potential Candidate in Cardiovascular Disease |
title_sort | dpp4 as a potential candidate in cardiovascular disease |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488155/ https://www.ncbi.nlm.nih.gov/pubmed/36147690 http://dx.doi.org/10.2147/JIR.S380285 |
work_keys_str_mv | AT chensiyu dpp4asapotentialcandidateincardiovasculardisease AT kongxiangquan dpp4asapotentialcandidateincardiovasculardisease AT zhangkefan dpp4asapotentialcandidateincardiovasculardisease AT luoshuai dpp4asapotentialcandidateincardiovasculardisease AT wangfeng dpp4asapotentialcandidateincardiovasculardisease AT zhangjunjie dpp4asapotentialcandidateincardiovasculardisease |